Phase 2RecruitingAge-related condition
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Phase 2 Study of Venetoclax-containing Therapy in Combination With HLA-mismatched Mobilized Peripheral Blood Mononuclear Cell Infusion for Intermediate-risk and Higher Myelodysplastic Syndromes
- Sponsor
- Beijing 302 Hospital (Academic or other)
- Enrolment
- 40 planned
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Venetoclax; Azacitidine (AZA) or Decitabine (DAC); GPBMC infusion
- Ages
- adults, older adults
- Registry
- NCT07238686
Full record on ClinicalTrials.gov
From the registry
This study aims to evaluate the safety and efficacy of a Venetoclax and hypomethylating agent-based regimen combined with infusion of HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cells (GPBMC) in patients with intermediate-risk and higher myelodysplastic syndromes who are ineligible for allogeneic hematopoietic stem cell transplantation.
Primary outcomes
- Overall survival (OS)
- Overall response rate (ORR)
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started